| # | Title | Journal | Year | Citations |
|---|
| 1 | Crohn's disease | Lancet, The | 2012 | 1,722 |
| 2 | Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference | Gastroenterology | 2018 | 712 |
| 3 | Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease | Clinical Gastroenterology and Hepatology | 2019 | 322 |
| 4 | Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease | Gastroenterology | 2021 | 145 |
| 5 | Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges | Gut | 2020 | 127 |
| 6 | ACG Clinical Guidelines: Clinical Use of Esophageal Physiologic Testing | American Journal of Gastroenterology | 2020 | 111 |
| 7 | TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial | Gastroenterology | 2021 | 101 |
| 8 | NAFLD: Reporting Histologic Findings in Clinical Practice | Hepatology | 2021 | 86 |
| 9 | Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD | Nature Reviews Endocrinology | 2022 | 82 |
| 10 | MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis | Gut | 2021 | 78 |
| 11 | Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results | Hepatology | 2009 | 75 |
| 12 | Practice patterns in NAFLD and NASH: real life differs from published guidelines | Therapeutic Advances in Gastroenterology | 2016 | 72 |
| 13 | MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis | Journal of Hepatology | 2022 | 67 |
| 14 | Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis | Gastroenterology | 2022 | 53 |
| 15 | Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis | Clinical Infectious Diseases | 2018 | 51 |
| 16 | Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH | Alimentary Pharmacology and Therapeutics | 2021 | 51 |
| 17 | Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications | Alimentary Pharmacology and Therapeutics | 2019 | 50 |
| 18 | Reduction of chronic hepatitis B‐related hepatocellular carcinoma with anti‐viral therapy, including low risk patients | Alimentary Pharmacology and Therapeutics | 2016 | 47 |
| 19 | Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease | Alimentary Pharmacology and Therapeutics | 2021 | 40 |
| 20 | Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis | Hepatology | 2022 | 39 |
| 21 | AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity | Gastroenterology | 2022 | 39 |
| 22 | Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality | Alimentary Pharmacology and Therapeutics | 2022 | 38 |
| 23 | Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab | American Journal of Transplantation | 2022 | 33 |
| 24 | Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease | Alimentary Pharmacology and Therapeutics | 2022 | 32 |
| 25 | Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions | Hepatology | 2021 | 30 |
| 26 | Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis | Hepatology | 2022 | 29 |
| 27 | Contrast-Enhanced Ultrasound of Focal Liver Masses: A Success Story | Ultrasound in Medicine and Biology | 2020 | 26 |
| 28 | Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease | Hepatology Research | 2022 | 26 |
| 29 | MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis | Hepatology | 2021 | 24 |
| 30 | NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH | Hepatology | 2022 | 24 |
| 31 | Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study | The Lancet Gastroenterology and Hepatology | 2023 | 24 |
| 32 | The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care | Open Forum Infectious Diseases | 2015 | 22 |
| 33 | Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease | Clinical Gastroenterology and Hepatology | 2022 | 22 |
| 34 | Review article: current and emerging therapies for the management of cirrhosis and its complications | Alimentary Pharmacology and Therapeutics | 2022 | 20 |
| 35 | AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis | Gastroenterology | 2023 | 19 |
| 36 | Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis | Clinical Gastroenterology and Hepatology | 2022 | 18 |
| 37 | Chronic HBV infection outside treatment guidelines: is treatment needed? | Antiviral Therapy | 2012 | 17 |
| 38 | Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin | Alimentary Pharmacology and Therapeutics | 2023 | 17 |
| 39 | A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH | Hepatology Communications | 2019 | 16 |
| 40 | Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma | Clinical Gastroenterology and Hepatology | 2020 | 16 |
| 41 | Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy | Clinical Journal of Gastroenterology | 2021 | 16 |
| 42 | Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Inflammatory Bowel Disease | Journal of Clinical Gastroenterology | 2023 | 16 |
| 43 | Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease | Therapeutic Advances in Gastroenterology | 2021 | 15 |
| 44 | Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis | Alimentary Pharmacology and Therapeutics | 2022 | 15 |
| 45 | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score | Hepatology | 2022 | 15 |
| 46 | A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis | Alimentary Pharmacology and Therapeutics | 2023 | 15 |
| 47 | Cost-Related Nonadherence to Medications Among US Adults With Chronic Liver Diseases | Mayo Clinic Proceedings | 2021 | 13 |
| 48 | Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis | American Journal of Gastroenterology | 2023 | 13 |
| 49 | Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial | Hepatology Communications | 2021 | 12 |
| 50 | Post-endoscopy Esophageal Neoplasia in Barrett’s Esophagus: Consensus Statements From an International Expert Panel | Gastroenterology | 2022 | 12 |
